Premium
Profiling 200 biomarkers in cancer cell culture supernates and serum using Luminex® screening assays (1012.3)
Author(s) -
David James,
Anderson Michael,
O'Brien Isabel,
Schwartz Matthew,
Schmidt Jane
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1012.3
Subject(s) - multiplex , angiogenesis , cancer , metastasis , biomarker , cancer research , cancer cell , cell adhesion , immunology , biology , medicine , cell , bioinformatics , biochemistry
Cancer progression involves metabolic pathways related to cell growth and proliferation, adhesion, angiogenesis, apoptosis, and others. Multiple biomarkers in serum have been identified that are related to the presence of various cancers as well as the stage, metastatic potential and prognosis. Efforts to quantify changes in these biomarkers will enhance the understanding of the activation of cancer‐related pathways. The measurement of a single biomarker can have limited utility in such a complex disease as cancer, while multiplex profiling can lead to a better understanding of cancer biology and consequently to better diagnostic and therapeutic methods. Luminex® Screening Assays are highly flexible bead‐based multiplex assays. They allow up to 100 biomarkers, selected from a total of about 200 analytes, to be simultaneously profiled in cell culture supernates, serum or plasma samples. We measured a total of 200 analytes from a variety of cancer cell supernates and serum samples from individuals with a variety of cancers or apparently healthy individuals. The biomarkers tested included cancer antigens, cytokines, chemokines, growth factors, MMPs, protease inhibitors, and other markers. Starting with only 50 µL of each sample, we obtained quantitative results for biomarkers of cancer growth and metastasis, angiogenesis, matrix remodeling, cell adhesion, metabolic function, and cell death.